Completed PHASE4 INTERVENTIONAL 2-arm NCT02304081

Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function

Effect of Saxagliptin in Addition to Dapagliflozin and Metformin on Insulin Resistance, Islet Cell Dysfunction, and Metabolic Control in Subjects With Type 2 Diabetes Mellitus on Previous Metformin Treatment

Sponsor: Prof. Dr. Thomas Forst

Conditions Type2 Diabetes Mellitus

Interventions Placebo for Saxagliptin Saxagliptin

Updated 7 times since 2017 Last updated: Jun 18, 2018 Started: Jan 31, 2015 Primary completion: Aug 31, 2016 Completion: Aug 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Type2 Diabetes Mellitus and is currently completed. Prof. Dr. Thomas Forst leads this study, which shows 7 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jul 2018 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — Jul 2018 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Prof. Dr. Thomas Forst

Data source: Profil Mainz GmbH & Co KG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mainz, Germany